[go: up one dir, main page]

WO1996014089A1 - Procedes et compositions pour diagnostiquer des allergies aux puces - Google Patents

Procedes et compositions pour diagnostiquer des allergies aux puces Download PDF

Info

Publication number
WO1996014089A1
WO1996014089A1 PCT/US1995/013658 US9513658W WO9614089A1 WO 1996014089 A1 WO1996014089 A1 WO 1996014089A1 US 9513658 W US9513658 W US 9513658W WO 9614089 A1 WO9614089 A1 WO 9614089A1
Authority
WO
WIPO (PCT)
Prior art keywords
flea
ige
patient
allergen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/013658
Other languages
English (en)
Inventor
Genadie G. Sverlow
Joy L. Halverson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoogen Inc
Original Assignee
Zoogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoogen Inc filed Critical Zoogen Inc
Priority to AU39668/95A priority Critical patent/AU3966895A/en
Publication of WO1996014089A1 publication Critical patent/WO1996014089A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/4359—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from fleas

Definitions

  • the field of this invention is the diagnosis of flea allergies.
  • Allergens are a group of antigens that induce an immediate hypersensitivity reaction following interaction with cell-bound immunoglobulin E (IgE) molecules. Allergen extracts are frequently adminstered intradermally to detect or confirm the allergic status of a patient. Patients allergic to a particular antigen will respond with an inflammatory reaction at the site of the injection. Allergens have also been used in laboratory tests for allergy diagnosis by detecting the presence of allergen-specific IgE in the serum of patients.
  • IgE immunoglobulin E
  • Allergen extracts are frequently administered in controlled amounts and intervals (hyposensitization) as treatment for allergy. Recent evidence suggests that allergen peptides may act on T cells to uncouple the cellular interactions resulting in IgE-induced mast cell degranulation and inflammation. Allergy hyposensitization can be very effective, is easy to administer, and is well tolerated by a majority of patients.
  • Fleas, Ctenocephalides felis felis and others are now recognized as a major cause of physiological disorders among mammals. These insects are ectoparasites that attack dogs, cats, and humans. Certain species (i.e., dogs and cats), and individuals of these species are more allergic to fleabites than others, resulting in a clinical disorder called flea allergy dermatitis (FAD) or flea bite hypersensitivity.
  • FAD flea allergy dermatitis
  • the hallmark of FAD is intense pruritis (itching) not only at the site of the flea bite but in a distinctive, body- wide distribution.
  • This allergic reaction is a systemic response to a variety of protein substances in the oral secretions which the flea injects intradermally when it bites.
  • Flea allergy dermatitis is the most common skin malady of the pet dog population of the United States, with as many as 8-10 per cent of pet dogs living in temperate climates being affected. In addition, greater than 50 per cent of dogs with other skin diseases, such as pyoderma and seborrhea, have FAD as a major contributing factor. FAD is a relentless annoyance to dogs, cats and their owners, causing intense pruritus. The obsessive scratching and chewing produces open sores and areas of hair loss. Chronic FAD leads to scarring and permanent bald spots and is often associated with seborrhea, giving the dog a foul odor which pervades the household.
  • Flea allergy also is recognized as a contributory cause of the common dermatitis of man known as papular urticaria.
  • FAD FAD
  • the control is primarily insecticidal.
  • Various strong chemicals and medications are used on dogs.
  • the large range of chemicals that are on the market include chlorinated hydrocarbons, carbamates, organophosphates, pyrethroids, and insect growth regulators.
  • some dogs with extreme ectoparasite infestations may actually go into shock and die following vigorous treatment. Because some stages of the flea's life cycle persist for months in the environment, there is a need for repeated application of chemicals and for chemicals with residual action. Some chemicals with residual action may be toxic to the animal or humans.
  • Veterinarians use systemic corticosteroid therapy to relieve FAD symptoms temporarily.
  • many dogs in temperate climates require lifelong, chronic steroid treatment resulting in undesirable and even fatal consequences.
  • many veterinary clients are increasingly sophisticated and object to the long-term use of steroids in their pets. Veterinarians practicing in temperate climates are frustrated that they can offer no therapeutic options to their patients.
  • Methods and compositions are provided for performing diagnostic assays for the detection of flea allergies, utilizing the isolation, characterization, and expression of flea allergens.
  • the diagnostic methods include intradermal skin tests and immunoassays.
  • cDNA clones encoding major Ctenocephalides felis felis allergens are used to produce protein allergens.
  • the recombinant proteins retain the antigenicity of the native molecule, and are useful in diagnostic assays.
  • the protein compositions are also useful as therapeutics, particularly for hyposensitization of allergic patients.
  • Methods are provided for diagnostic assays and hyposensitization therapy of flea allergies, with recombinant proteins having the antigenicity of naturally produced proteins.
  • Methods for the isolation, characterization, and expression of flea allergens are provided.
  • the subject methods are used to make pure compositions of protein allergens from flea species, particularly Ctenocephalides felis felis.
  • the allergen proteins are expressed from DNA constructs comprising cloned DNAs, and are immunologically reactive with allergic patients.
  • the DNA compositions also find use in identifying proteins and the DNA sequences encoding proteins having homology to the flea allergens. Allergens are compounds which cause hypersensitivity reactions in mammals, generally mediated by immunoglobulin E.
  • the allergens of interest are proteins responsible for allergic dermatitis caused by blood sucking arthropods, e.g. Diptera, including mosquitos (Anopheles sp., Aedes sp., Culiseta sp., Culex sp.); flies ⁇ Phlebotomus sp., Culicoides sp.) particularly black flies, deer flies and biting midges; ticks (Dermacenter sp., Ornithodoros sp., Otobius sp.); fleas, e.g. the order Siphonaptera, including the genera Xenopsylla, Pulex and Ctenocephalides.
  • RNA is isolated from the arthropod species of interest by conventional methods.
  • the mRNA source animals may be cultured on suitable media, or may be isolated from an animal host.
  • the mRNA is reverse transcribed and cloned into a suitable expression library, conveniently using a plasmid or lambda phage vector, e.g. ⁇ gtl 1 and variants thereof.
  • the library is plated under conditions which allow expression of the cloned DNA.
  • a preparation of antiserum from an allergic animal is used to screen the library.
  • the animal(s) chosen for an antiserum sample will be allergic to the particular insect species from which the library was made. This may be verified by monitoring the reaction to insect bites.
  • Mammalian species susceptible to allergic dermatitis include those of the family Canidae, e.g. dogs, wolves, coyotes, foxes and jackals; the family Felidae, e.g.
  • Antisera is prepared from a biological sample, usually a blood derivative, e.g. plasma or serum. Whole serum or plasma, diluted as necessary, may be used for screening. Greater specificity may be obtained by isolating the IgE fraction, usually by affinity chromotography using reagents specific for IgE, e.g. anti-IgE antisera, Staphylococcus protein G, etc.
  • Detection of IgE binding to the library may be achieved by a number of conventional methods. It is convenient to transfer phage plaques or colonies to nitrocellulose filters, followed by binding of the IgE antiserum to the filters. The presence of bound antibody may be detected by use of a second stage antibody with specificity for IgE and having a detectable label, e.g. horseradish peroxidase, phosphatase, radioactive labels, etc.
  • the plaques which specifically bind the antisera are isolated, and the cDNA insert further characterized as to DNA sequence, antisera reactivity, etc.
  • Cten f I SEQ ID NO: 1
  • Cten f II SEQ ID NO:3
  • Cten f III SEQ ID NO:5
  • Genes shall be intended to mean the nucleotide sequences encoding the specific protein allergens, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression of the protein encoded by the genes, and will include up to about the length of the mature mRNA.
  • flanking genomic sequence may include up to 1 kb of flanking genomic DNA at either the 5' or 3' end, and as much as 10 kb of flanking genomic sequence.
  • non-coding sequences include terminator and polyadenylation sequences, regulatory protein binding sequences, transcriptional sequences, and the like.
  • Cten f I (SEQ ID NOJ) contains an open reading frame from nucleotide 47 to nucleotide 392, which encodes a polypeptide of approximately 13,000 daltons (SEQ ID NO:2).
  • Cten f II (SEQ ID NO:3) contains an open reading frame from nucleotide 58 to nucleotide 421 , which encodes a polypeptide of approximately 14,000 daltons (SEQ ID NO:4).
  • Cten f III (SEQ ID NO:5) contains an open reading frame from nucleotide 65 to nucleotide 293, which encodes a polypeptide of approximately 9,000 daltons (SEQ ID NO:6).
  • a comparison of the DNA sequence with a database of known sequences reveals no obvious similarities between the three Cten f sequences, or with other sequences.
  • the nucleic acid compositions of the subject invention may be genomic or cDNA sequences encoding all or a part of the subject flea allergens.
  • the cDNA gene may then be used to isolate the genomic gene in accordance with conventional techniques.
  • Fragments may be obtained of the cDNA or genomic sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc.
  • fragments will be of at least 12 nt, more usually at least 18 nt
  • fragments will include a functional epitope.
  • the sequence providing for a functional epitope can be determined by expression of the sequence, and assaying for reactivity of the expression product with allergen specific antibodies by conventional immunoassay.
  • the DNA sequences may be obtained in substantial purity, and will be obtained as a sequence other than a sequence of an intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid compounds which do not include a Cten f sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", i.e. flanked by one or more nucleotides with which they are not normally associated with on a natural chromosome.
  • the DNA sequences may be used in a variety of ways. They may be used as probes for identifying homologous allergens from other species causing allergic dermatitis, particularly other blood-sucking arthropods, as previously described. Homologous sequences are those with substantial sequence similarity to Cten f sequences, i.e. at least 80%, preferably at least 90%, more preferably at least 95% sequence identity with the nucleotide sequence of a Cten f sequence. Allergens from other flea species, i.e. Xenopsylla sp., Pulex sp., Ctenocephalides canis, etc. are of particular interest.
  • homologous nucleic acid sequences will be detected by hybridization under low stringency conditions, for example, at 50° C and 10XSSC (0.9 M saline/0.09 M sodium citrate) and remain bound when subject to washing at 55°C with lXSSC.
  • the DNA may also be used to identify cells or organs which are expressing Cten genes.
  • the manner in which one probes cells for the presence of particular nucleotide sequences, particularly as DNA, mRNA or cDNA, is well-established in the literature and does not require elaboration here.
  • mRNA may be isolated free of DNA, and by using reverse transcriptase and PCR with primers specific for the various allergens, the cDNAs of the allergens may be expanded, separated on gel electrophoresis and then probed using Southern blotting or sequencing. Other techniques may also find use.
  • the DNA sequences may be inserted into an appropriate expression vector, where the native transcriptional initiation region may be employed or an exogenous transcriptional initiation region, i.e. a promoter other than the promoter which is associated with the gene in the normally occurring chromosome.
  • the promoter may be introduced by recombinant methods in vitro, or as the result of homologous integration of the sequence into a chromosome.
  • a wide variety of transcriptional initiation regions are known for a wide variety of expression hosts, where the expression hosts may involve prokaryotes or eukaryotes, particularly E. coli, B. subtilis, mammalian cells, such as CHO cells, COS cells, monkey kidney cells, lymphoid cells, particularly human cell lines, and the like.
  • a selectable marker operative in the expression host will be present.
  • the promoter may be operably linked to the coding sequence of the genes of interest so as to produce a translatable mRNA transcript encoding Cten f I, II, and III.
  • Expression vectors have convenient restriction sites located near the promoter sequence so as to provide for the insertion of nucleic acid sequences encoding heterologous proteins.
  • the promoters in suitable expression vectors may be either constitutive or inducible.
  • Expression vectors for the production of fusion proteins, where the exogenous fusion peptide provides additional functionality, i.e. increased protein synthesis, stability, reactivity with defined antisera, an enzyme marker, e.g. ⁇ -galactosidase, etc., are of particular interest.
  • Expression cassettes may be prepared comprising the transcription initiation region, which may be constitutive or inducible, with or without an enhancer sequence, including the endogenous or heterologous enhancer sequence, the gene encoding the subject allergens or fragment thereof, and a transcriptional termination region, optionally having a signal for attachment of a poly A sequence.
  • the gene may be genomic, including the native introns, or cDNA gene, or portion thereof.
  • sequences which allow for the expression of functional epitopes usually at least about 24 nucleotides in length, more usually at least about 48 nucleotides in length, and up to the complete open reading frame of the gene.
  • a functional epitope is an allergen polypeptide which is sufficient to bind allergen specific antibodies.
  • Functional epitopes can be assayed by testing the binding of the polypeptide in a convenient immunoassay with allergen specific antibodies.
  • the cells containing the construct may be selected by means of a selectable marker, the cells expanded and then used for expression.
  • a signal peptide may be joined to the sequence encoding the subject proteins or fragments thereof, whereby the protein will be expressed, translocated through the cell membrane, and processed to remove the signal peptide.
  • the expression cassettes may be introduced into a variety of vectors, where the vectors will normally be characterized by the ability to provide selection of cells comprising the expression vectors.
  • the vectors may provide for extrachromosomal maintenance, particularly as plasmids in bacteria or viruses in eukaryotic cells, or for integration, particularly in mammalian cells.
  • extrachromosomal maintenance is desired, an origin sequence will be provided for the replication of the plasmid, which may be a low- or high-copy plasmid.
  • markers are available for selection, particularly those which protect against toxins, more particularly against antibiotics. The particular marker which is chosen will be selected in accordance with the nature of the host, where in some cases, complementation may be employed with auxotrophic hosts, e.g. yeast.
  • Introduction of the DNA construct may be by any convenient means, e.g.
  • the subject polypeptide compositions will include the entire Cten f proteins, having the amino acid sequences Cten f I (SEQ ID NO:2), Cten f II (SEQ ID NO:4) and Cten f III (SEQ ID NO:6), collectively refered to as Cten f proteins. Also included are useful fragments thereof, usually having at least about 8 amino acids, more usually at least about 16 amino acids, particularly involving all or a major portion of an epitope.
  • Purity will be at least about 50 wt.% of the protein present, preferably at least about 90 wt.%, more preferably substantially free of other proteins, particularly other flea or diptera proteins and cell debris. Protein compositions for injection will desirably be free of bacterial endotoxins.
  • the allergens may be formulated as a single species, or as a cocktail comprising one or more of the Cten f proteins. A cocktail will usually comprise at least about 10% total protein weight of each of the allergen proteins.
  • the subject compositions may be modified in a variety of ways, such as conjugation with labels, e.g. radioisotopes, particles, e.g. magnetic, specific binding pair members, e.g. biotin and avidin, enzymes, fluorescers, etc., particularly labels which provide, directly or indirectly, a detectable signal.
  • labels e.g. radioisotopes, particles, e.g. magnetic, specific binding pair members, e.g. biotin and avidin, enzymes, fluorescers, etc.
  • the subject compositions may be conjugated to polypeptides or proteins, either fused or through a chemical linker to provide novel properties to the protein, e.g. extended lifetime, attachment to a target site by means of a ligand or antibody, or the like.
  • the subject compositions may be used for producing antibodies specific for one or more epitopes of the Cten f proteins.
  • the antibodies may be produced in accordance with conventional ways, immunization of a mammalian host, e.g. mouse, rat, guinea pig, cat, dog, etc., fusion of resulting splenocytes with a fusion partner for immortalization and screening for antibodies having the desired affinity to provide monoclonal antibodies having a particular specificity.
  • These antibodies can be used for affinity chromatography, for identifying other allergens having similar epitopes to the subject proteins, and the like.
  • the antibodies may find particular use as a competitor for patient anti-allergen antibodies in diagnostic assays. Those antibodies may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other label which will allow for detection of complex formation between the labeled antibody and its complementary epitope.
  • the subject polypeptide compositions are particularly useful for diagnosis and treatment of flea allergies.
  • Patients in which such allergies may be diagnosed include canines, felines and primates, particularly humans and domesticated cats and dogs.
  • the Cten f allergens have been shown to react strongly with IgE from allergic canines, and are useful in diagnosing such allergies.
  • the polypeptide compositions for diagnosis and treatment will be produced in accordance with the previously described methods.
  • Formulations for injection will comprise a physiologically-acceptable medium, such as saline, PBS, aqueous ethanol, aqueous ethylene glycols, or the like.
  • a cocktail of allergens will be used, usually from a single arthropod species.
  • it may be desirable to perform assays to determine the particular polypeptide species responsible for the allergic reaction in which case a formulation will include a single polypeptide species.
  • Allergy diagnosis may be performed by a number of methods.
  • the different methods all determine the presence of an IgE response to the allergen in a patient, where a positive response is indicative of an allergic condition.
  • the IgE response may be determined by determination of antibody binding, or by the presence of a response to intradermal challenge with antigen.
  • a dose of allergen formulated as a cocktail of Cten f proteins or as individual Cten f protein species, in a suitable medium is injected subcutaneously into the patient.
  • the dose of antigen will usually be at least about 0.05 ⁇ g of protein, and usually not more than about 5 ⁇ g of protein.
  • a control comprising medium alone, or an unrelated protein will be injected nearby at the same time.
  • the site of injection is examined after a short period of time, usually at least about 15 minutes and not more than about 45 minutes, for the presence of a wheal.
  • the wheal at the site of allergen injection is compared to that at the site of the control injection, usually by measuring the size of the wheal.
  • the skin test readings may be assessed by a variety of objective grading systems.
  • a positive result for the presence of an allergic condition will show an increased diameter at the site of allergen injection as compared to the control, usually at least about 50% increase in size, more usually at least 100% increase in size. It is standard procedure to carry out tests in duplicate or triplicate.
  • An alternative method for diagnosis depends on the in vitro detection of binding between IgE in a patient sample and the subject allergens, either as a cocktail of Cten f proteins or as individual Cten f protein species, where the presence of specific binding is indicative of an allergic condition.
  • Measuring the concentration of an allergen specific IgE in a sample or fraction thereof may be accomplished by a variety of specific assays. In general, the assay will measure the reactivity between a patient sample, usually blood derived, generally in the form of plasma or serum.
  • the IgE fraction may be purified from the patient sample by various affinity methods, e.g.
  • Staph protein G, anti-IgE antibodies, etc., or more conveniently, a specific anti-IgE reagent may be used for detection of binding.
  • the patient sample may be used directly, or diluted as appropriate, usually about 1 :10 and usually not more than about 1:10,000.
  • Immunoassays may be performed in any physiological buffer, e.g. PBS, normal saline, HBSS, dPBS, etc.
  • a conventional sandwich type assay is used.
  • a sandwich assay is performed by first attaching the allergen to an insoluble surface or support.
  • the allergen may be bound to the surface by any convenient means, depending upon the nature of the surface, either directly or through specific antibodies. The particular manner of binding is not crucial so long as it is compatible with the reagents and overall methods of the invention. They may be bound to the plates covalently or non-covalently, preferably non-covalently.
  • the insoluble supports may be any compositions to which allergen polypeptides can be bound, which is readily separated from soluble material, and which is otherwise compatible with the overall method of measuring IgE.
  • the surface of such supports may be solid or porous and of any convenient shape.
  • suitable insoluble supports to which the receptor is bound include beads, e.g. magnetic beads, membranes and microtiter plates. These are typically made of glass, plastic (e.g. polystyrene), polysaccharides, nylon or nitrocellulose. Microtiter plates are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples.
  • the non-specific binding sites on the insoluble support i.e. those not occupied by allergen, are generally blocked.
  • Preferred blocking agents include non-interfering proteins such as bovine serum albumin, casein, gelatin, and the like.
  • non-interfering proteins such as bovine serum albumin, casein, gelatin, and the like.
  • detergents at non-interfering concentrations such as Tween, NP40, TX100, and the like may be used.
  • Samples, fractions or aliquots thereof are then added to separately assayable supports (for example, separate wells of a microtiter plate) containing support-bound allergen.
  • separately assayable supports for example, separate wells of a microtiter plate
  • a series of standards, containing known concentrations of IgE is assayed in parallel with the samples or aliquots thereof to serve as controls.
  • each sample and standard will be added to multiple wells so that mean values can be obtained for each.
  • the incubation time should be sufficient for IgE molecules to bind the insoluble allergen. Generally, from about 0J to 3 hr is sufficient, usually 1 hr sufficing.
  • the insoluble support is generally washed of non-bound components.
  • a dilute non-ionic detergent medium at an appropriate pH, generally 7-8, is used as a wash medium. From one to six washes may be employed, with sufficient volume to thoroughly wash non-specifically bound proteins present in the sample.
  • a solution containing patient antibody specific second receptor in most cases patient IgE specific second receptor, is applied.
  • the receptor may be any compound which binds patient antibodies with sufficient specificity such that it can be distinguished from other components present.
  • second receptors are antibodies specific for patient IgE, either monoclonal or polyclonal sera, e.g. mouse anti-human IgE, mouse anti-dog IgE, rabbit anti-cat IgE, etc.
  • IgE specific receptors may be labelled to facilitate direct, or indirect quantification of binding.
  • labels which permit direct measurement of second receptor binding include radiolabels, such as ⁇ H or 125 ⁇ fluorescers, dyes, beads, chemilumninescers, colloidal particles, and the like.
  • labels which permit indirect measurement of binding include enzymes where the substrate may provide for a colored or fluorescent product.
  • the second receptors are antibodies labeled with a covalently bound enzyme capable of providing a detectable product signal after addition of suitable substrate.
  • suitable enzymes for use in conjugates include horseradish peroxidase, alkaline phosphatase, malate dehydrogenase and the like.
  • the second receptor may be unlabeled.
  • a labeled second receptor-specific compound is employed which binds to the bound second receptor.
  • Such a second receptor-specific compound can be labelled in any of the above manners. It is possible to select such compounds such that multiple compounds bind each molecule of bound second receptor. Examples of second receptor/second receptor- specific molecule pairs include antibody/anti-antibody and avidin (or streptavidin)/biotin. Since the resultant signal is thus amplified, this technique may be advantageous where only a small amount of IgE is present.
  • An example is the use of a labeled antibody specific to the second receptor.
  • the second receptor is a rabbit anti-allotypic antibody
  • an antibody directed against the constant region of rabbit antibodies provides a suitable second receptor specific molecule.
  • the anti- immunoglobulin will usually come from any source other than human, such as ovine, rodentia, particularly mouse, or bovine.
  • the volume, composition and concentration of IgE specific receptor solution provides for measurable binding to the IgE already bound to receptor.
  • the concentration will generall_ e sufficient to saturate all IgE potentially bound to allergen.
  • the concentration generally will be about 0J to 50 ⁇ g/ml, preferably about 1 ⁇ g/ml.
  • the solution containing the second receptor is generally buffered in the range of about pH 6.5-9.5.
  • the solution may also contain an innocuous protein as previously described.
  • the incubation time should be sufficient for the labeled ligand to bind available molecules. Generally, from about 0J to 3 hr is sufficient, usually 1 hr sufficing.
  • the insoluble support is generally again washed free of non- specifically bound second receptor, essentially as described for prior washes.
  • the signal produced by the bound conjugate is detected by conventional means.
  • an enzyme conjugate an appropriate enzyme substrate is provided so a detectable product is formed. More specifically, where a peroxidase is the selected enzyme conjugate, a preferred substrate combination is H2O2 and is O- phenylenediamine which yields a colored product under appropriate reaction conditions. Appropriate substrates for other enzyme conjugates such as those disclosed above are known to those skilled in the art.
  • reaction conditions as well as means for detecting the various useful conjugates or their products are also known to those skilled in the art.
  • light absorbance at 490-495 nm is conveniently measured with a spectrophotometer.
  • the amount of bound IgE detected will be compared to control samples from non-allergic animals.
  • the presence of increased levels of allergen specific IgE is indicative of an allergic condition, usually at least about a 10 fold increase will be taken as a positive reaction.
  • a competitive assay will be used.
  • a competitor to the IgE is added to the reaction mix.
  • the competitor and the IgE compete for binding to the allergen.
  • the competitor molecule will be labeled and detected as previously described, where the amount of competitor binding will be proportional to the amount of IgE present.
  • the concentration of competitor molecule will be from about 10 times the maximum anticipated IgE concentration to about equal concentration in order to make the most sensitive and linear range of detection.
  • An alternative protocol is to provide anti-patient IgE bound to the insoluble surface. After adding the sample and washing away non-specifically bound proteins, one or a combination of the subject allergens are added, where the allergens are labeled so as not to interfere with the allergen binding to the IgE. Conveniently, fused proteins may be employed, where the allergen peptide sequence is fused to an enzyme sequence, e.g. ⁇ -galactosidase.
  • the apparatus will generally employ a continuous flow-path of a suitable filter or membrane, having at least three regions, a fluid transport region, a sample region, and a measuring region.
  • the sample region is prevented from fluid transfer contact with the other portions of the flow path prior to receiving the sample. After the sample region receives the sample, it is brought into fluid transfer relationship with the other regions, and the fluid transfer region contacted with fluid to permit a reagent solution to pass through the sample region and into the measuring region.
  • the measuring region may have bound to it the allergen, with a conjugate of an enzyme with an IgE specific antibody employed as a reagent, generally added to the sample before application.
  • the allergen may be conjugated to an enzyme, with IgE specific antibody bound to the measurement region.
  • Other immunoassays are known in the art and may find use as diagnostics.
  • Ouchterlony plates provide a simple determination of antibody binding, although they will not easily differentiate between IgE and IgG binding.
  • Western blots may be performed on protein gels or protein spots on filters, using a detection system specific for IgE as desired, conveniently using a labeling method as described for the sandwich assay.
  • the subject protein composition may find application in therapy, particularly for hyposensitization of patients susceptible to flea specific allergies.
  • These include intradermal, subcutaneous or intramuscular injections with aqueous allergen formulated in a physiologically acceptable medium, either singly or as a cocktail, or with allergen in an adjuvant, generally an alum precipitate.
  • Adjuvants will not usually be necessary, but may be included.
  • the use of adjuvants generally increases the interval between injections.
  • the amount of allergen to be injected may be empirically derived, and will depend on the size of the animal, usually at least about 100 ng allergen kilogram of body weight, and not more than about 1 mg allergen/kilogram body weight. Frequently the dose will be increased through the course of injections by as much as about ten to one hundred fold.
  • the number of injections in an initial series will usually be at least about 5 injections, and may be as many as about 20 injections, or until there are positive signs of improvement.
  • the frequency of injections for an initial series will be from about every 3 to about every 7 days for an aqueous formulation and from about 7 to from about 21 days for an adjuvant formulation.
  • Booster injections may be administered less frequently, from about every week to as infrequently as every one to three months. It will be appreciated that therapy must be tailored to the individual's response.
  • the total number of injections may vary according to the time of year therapy is started, and the patient's response to therapy. Booster injections after the initial series will be performed seasonally if appropriate, or with the incidence of signs of dermatitis. There is often an advantage to giving periodic boosters during the non-allergy season for patients with a seasonal allergic pattern.
  • the injections are continued until either a therapeutic effect becomes evident, evidenced as a decrease in allergic symptoms, e.g. pruritis, dermatitis, inflammation, etc., or blocking antibodies develop, usually detected as an increase in specific IgG titer.
  • the detection of blocking antibodies may be performed essentially as described for the detection of IgE antibodies, using IgG specific reagents for detection.
  • mRNA Messenger RNA
  • mRNA messenger RNA
  • Polyadenylated mRNA was isolated, extracted, sedimented, and affinity purified on an oligo (dT)-cellulose column according to protocols of a Fast TrackTM kit from Invitrogen, using the reagents and buffers provided by Invitrogen.
  • the mRNA was reverse transcribed into cDNA, which was cloned into lambda gtl 1, and the resulting cDNA library was screened by using antibodies from patients with flea allergy dermatitis. Phage-producing plaques reactive with the antiserum were rescreened to finally obtain a purified clone for further examination.
  • the protocol for mRNA isolation is as follows:
  • Ground fleas were transferred to a 50 ml conical tube containing 15 ml of Stock Buffer and 300 microliters ( ⁇ l) RNase-Protein degrader. The contents were homogenized at full speed with a Brinkman hand held homogenizer for about 30 seconds. The tube was then placed in a 45° C water bath for 1 hour.
  • Insoluble material was sedimented at 4000g for 5 minutes at room temperature, and the supernatant was transferred to a fresh tube. NaCl concentration was adjusted by adding 0.95 ml of 5M NaCl. DNA was sheared by passing lysate 3 or 4 times through a sterile plastic syringe fitted with a 21 gauge needle.
  • oligo dT cellulose tablet was added to the tube and allowed to swell for 2 minutes before crushing with a sterile pipet. The solution was mixed well and placed on a shaker at low speed for 60 minutes. The oligo dT cellulose was pelleted at 4000g for 5 minutes at 18° C. The supernatant was removed and the pellet resuspended in 20 ml of Binding Buffer. The solution was pelleted again at 4000g for 5 minutes, the supernatant was removed and the pellet resuspended in 10 ml of Binding Buffer. The solution was pelleted again and resuspended in 10 ml Low Salt Wash Buffer. The Low Salt wash was repeated two times, and after the last wash, the pellet was resuspended in 0.8 ml Low Salt Wash Buffer.
  • the sample was then pipetted into a spin column in a microfuge tube and sedimented at 18° C for 10 seconds at full speed.
  • the sample in the spin column was resuspended in 0.8 ml Low Salt Wash Buffer. This process was repeated two additional times.
  • the spin column was placed into a new microfuge tube and 0.2 ml of Elution Buffer was added and mixed well.
  • the tube was sedimented for 10 seconds and 0.2 ml Elution Buffer was added to the spin column and mixed well.
  • the tube was sedimented again for 1 minute to collect all the liquid in the microfuge tube.
  • the mRNA was precipitated by adding 0J5 volumes of 2M Sodium Acetate and 2.5 volumes of 95% ethanol.
  • the tube was mixed well and frozen at -20° C for approximately 16 hours.
  • the tube was sedimented at full speed at 4° C in a microfuge for 15 minutes, and the supernatant was removed.
  • 0.5 ml of 70% ethanol was added and mixed.
  • the tube was sedimented at full speed at 4° C for 5 minutes, and the supernatant removed.
  • the pellet was resuspended in 20 microliters Elution Buffer.
  • the Promega RibocloneTM kit with AMV Reverse Transcriptase was utilized to synthesize the blunt ended cDNAs.
  • the protocol (all elements were included in the kit except mRNA) is as follows:
  • the pellet was resuspended in 15 ⁇ l sterile water and the following was added:
  • the solution was mixed well and quickly sedimented.
  • the mixture was incubated at 15 0 C for 16 hours.
  • the pellet was washed with 70% ethanol and sedimented for 5 minutes. The ethanol was removed and the pellet was resuspended in 16 ⁇ l sterile water. 2 ⁇ l of 10X Kinase Buffer (Pharmacia One-Phor-AllTM plus lOmM ATP) and
  • the gel slice was placed in a 2 ml reaction tube and heated to 70° C for 10 minutes, to allow the gel slice to melt.
  • the melted mixture was incubated at 40° C for 5 minutes, and then 1/10 volume of 10X beta-agarase buffer (NEB) and 10 ⁇ l beta- agarase (NEB. 1 unit/ ⁇ l) was added.
  • the mixture was incubated at 40° C for 1 hour.
  • the mixture was placed on ice for 5 minutes to confirm complete digestion of the agarose.
  • An equal volume of phenol/chloroform (1 : 1 ) was added and mixed for 1 minute.
  • the sample was mixed for 3 minutes and the top phase was removed into a new microfuge tube. 0J5 volumes of 2 M sodium acetate and an equal volume of isopropanol was added.
  • the sample was mixed by inverting several times and placed at 4° C for 16 hours.
  • the sample was sedimented for 15 minutes at 4° C in a microfuge, and the supernatant was removed.
  • the pellet was washed with 500 ⁇ l 70% ethanol and sedimented for 5 minutes. The supernatant was removed and the pellet was resuspended in 25ul water.
  • the ligations were incubated for 3 hours at 18° C.
  • the ligations were packaged by using Gigapack II Plus packaging extracts according to manufacturer's instructions (Stratagene) and incubated for 2 hours at 18° C. 500 ⁇ l SM buffer and 30 ⁇ l chloroform was added and mixed well.
  • Y1090 cells were transfected according to the following protocol: 10 ml Luria- Bertani medium with lOmM MgSO4, 0.2% Maltose was inoculated with a single Y1090 colony. The solution was incubated with shaking at 37° C for 4-6 hours. LB + MgSO4 plates were warmed to 37° C. The cells were diluted to OD ⁇ OO of 0.5 in 10 mM MgSO4 and placed on ice. Each packaged ligation was diluted 1:10 and 1:100 in SM and placed on ice. 200 ml Y1090 cells were placed into each Falcon 2059 tubes and 1 ⁇ l of each dilution and 1 ⁇ l undiluted packaging reactions was added. The mixture was incubated at 37° C for 15 minutes and 3 ml Top Agarose (IPTG/Xgal) was added, mixed by inverting and poured onto plates. The plates were incubated at 37° C for 16 hours.
  • IPTG/Xgal IPTG/Xgal
  • Plaques were counted to calculate the library titer.
  • Nine clear plaques and 1 blue plaque were picked for PCR analysis.
  • a plaque was placed in a PCR tube and 25 ⁇ l 2X PCR buffer was added. The samples were heated to 100° C in a PCR apparatus for 10 minutes.
  • 25 ⁇ l of the following cocktail was added: lambda gtl 1 forward and reverse primers (50 ng each), dNTP (250 mM final), Taq polymerase (1 unit), and water to 50 ⁇ l, mixed well and amplified for 30 cycles of 1 minute at 94° C, 1 minute at 55° C, and 1 minute at 72° C, with a final extension of 10 minutes at 72° C.
  • Ten ⁇ l of PCR product was run on a 1 % agarose gel to determine the average insert size.
  • the library was amplified by plating 50,000 pfu/plate on each of 20 LB plates
  • Serum samples were collected from over 20 dogs where flea allergy dermatitis was diagnosed visually by a veterinarian or from their clinical history of fleas and/or pruritis and chronic lumbo-sacral skin lesions. Each serum obtained was screened for high IgE titer against total flea extracts. The sera which generated the highest intensity signal to specific allergens on Western blots was further purified using either Protein G sepharose (Pharmacia) and/or preabso ⁇ tion with non-recombinant E. coli lysate. Dog IgE was not bound to Protein G-Sepharose, while 100% of IgG, 95% of IgA, and 44% of IgM were bound to Protein G-Sepharose.
  • the library produced by the method of Example I was screened by immunoassay, using a canine anti-Cten f I, II and III antiserum. Phage were plated at approximately 15,000 plaque-forming units per 150 mm Petri plate. For immunodetection of expressed proteins in E. coli Y1090 transfected with lambda gtl 1 constructs, plaque-forming units were incubated for 3.5 hours at 42° C, then transferred onto nitrocellulose containing 10 mM isopropyl- ⁇ -D-thiogalactopyranoside. After an incubation period of 3.5 hours at 37° C, the filters were placed in Western buffer for 3 hours at 18° C.
  • the membrane was then incubated with the ..era (RM8) diluted 1 :500 at 18° C. After 15 minute washes with Western buffer for 1 hour, the membrane was incubated with mouse anti-canine IgE at 1:500 for 3 hours at 18° C. After washing the membrane as before, the final incubation was done with IgG-HRP labeled antibody at 1 :4,000. The membrane was washed as previously. The membrane was then developed using the enhanced chemiluminescent (ECL) Western blotting detection system. Several phage clones reacted with the dog antiserum. Positive signals of varying intensity were seen.
  • ECL enhanced chemiluminescent
  • the DNA inserts were subcloned into pCRII (Invitrogen) and DNA sequencing was performed by the chain termination method both manually and using an autosequencer (Applied Biosystems).
  • the nucleotide sequence analysis of the cDNA insert (pCten f I, II, and III) were performed on both strands.
  • the cDNA sequence and the deduced amino acid sequence derived from cDNA inserts are provided as follows:
  • a 620 bp (SEQ ID NO:5) fragment was subcloned intothe EcoRI site.
  • the solution was mixed and adjusted to pH7.0 with NaOH.
  • the volume was adjusted to 1000 ml and sterilized by autoclaving. After autoclaving, 10 ml of sterile 1M
  • IPTG 500 ⁇ l of 1 mM IPTG was spread on surface-dried SOB plus ampicillin plates to create IPTG plates.
  • Circular nitrocellulose filters (82-mm) were immersed in 1 mM IPTG and dried completely on Whatman paper. Each IPTG filter was placed on IPTG plates.
  • the plates were incubated at 37° C for about 5 hours.
  • the filters were removed and placed on damp paper towels.
  • the colonies on the filters were exposed to chloroform vapor for 30 minutes.
  • the filters were transferred to lysis buffer at 18° C for about 16 hours with gentle agitation.
  • Recombinant clones expressing Cten f I, II, and III fragments in the correct orientation were detected by colony immunoassay and chosen for further analysis.
  • the Invitrogen Xpress System Protein Purification KitTM was used in the following steps. The cells were resuspended in 3 ml of Guanidinium Lysis Buffer, pH7.8 (equilibrated to 37° C). The cell mixture was gently rocked for 30 minutes at 18° C. The cell mixture was passed through a small gauge needle to lyse the cells and shear DNA and RNA. The insoluble debris was removed by sedimentation.
  • the clarified lysate was batch bound by resuspending the pre-equilibrated column with the 3ml lysate.
  • the column with the lysate was gently rocked for 30-60 minutes at 1 ° C.
  • the resin was allowed to settle by gravity and the supernatant was discarded.
  • the concentrate was washed four times with 0.5 M Tris-HCl, pH 6.8, using the same microcon-10 unit, to remove traces of urea.
  • the solution was concentrated to about 300 ⁇ l using the microcon- 10 unit.
  • Ten ⁇ l of purified protein was loaded on a precast 10-20% (w/v) polyacrylamide gradient gel (BioRad). The proteins were transferred electrophoretically onto a nitrocellulose filter. The protein blot was blocked in Western buffer for about 3 hours at 18° C. The blot was then incubated in the patient anti-sera described in Example 2 at 1:250 dilution at 4° C for 16 hours.
  • the membrane was washed thoroughly in Western buffer and incubated with an anti-canine IgE monoclonal at 1 :500 dilution for about 3 hours at 18° C.
  • the membrane was washed thoroughly again and probed with polyclonal anti-mouse IgG- HRP at 1 :6,000 dilution for 2 hours at 18° C.
  • the protein image was developed by using the enhanced chemiluminescence assay system (Amersham). The results showed that each of the three cDNA clones expressed a single immunoreactive protein. In all three cases the protein was the appropriate molecular weight for the fusion product.
  • TAATCAAAGG CAACAAAATG CTCCAAGAAA GTAAATGTTC ATATTTTAAA TAAAAAAACG 420
  • MOLECULE TYPE cDNA
  • xi SEQUENCE DESCRIPTION: SEQ ID NO: 3:
  • TCGTCGCCGC CAATCCCCAT ATGGAAACCG TCGATATTCA GCCATGTGCC TTCTTCCGCG 420

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention a pour objet des procédés pour l'isolement, la caractérisation et l'expression des allergènes de puces. Des clones ADNc codant trois principaux allergènes Ctenocephalides felis felis sont prévus, à savoir: (pCten f I, pCten f II, pCten f III). Les clones contiennent des zones de codage, et des caractéristiques structurelles impliquées dans la transcription et la traduction des allergènes de puces. Les protéines codées par les ADNc présentent un poids moléculaire d'environ 15000, 16000 et 11000 daltons, respectivement. Les protéines de recombinaison conservent le caractère antigénique de la molécule.
PCT/US1995/013658 1994-11-03 1995-10-10 Procedes et compositions pour diagnostiquer des allergies aux puces Ceased WO1996014089A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39668/95A AU3966895A (en) 1994-11-03 1995-10-10 Methods and compositions for the diagnosis of flea allergies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33395294A 1994-11-03 1994-11-03
US08/333,952 1994-11-03

Publications (1)

Publication Number Publication Date
WO1996014089A1 true WO1996014089A1 (fr) 1996-05-17

Family

ID=23304924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013658 Ceased WO1996014089A1 (fr) 1994-11-03 1995-10-10 Procedes et compositions pour diagnostiquer des allergies aux puces

Country Status (2)

Country Link
AU (1) AU3966895A (fr)
WO (1) WO1996014089A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037676A1 (fr) * 1996-04-10 1997-10-16 Heska Corporation Nouvelles proteines de salive d'ectoparasite et appareil pour les recueillir
WO1998005772A1 (fr) * 1996-08-01 1998-02-12 Heska Corporation Facteur de liberation de l'histamine, d'ectoparasites, leurs genes et utilisations
US5927230A (en) * 1994-10-07 1999-07-27 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
WO2000061621A3 (fr) * 1999-04-09 2001-07-05 Heska Corp Molecules d'acides nucleiques et proteines issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de malpighi de puces et utilisations correspondantes
US6372887B1 (en) * 1996-11-07 2002-04-16 Heska Corporation Flea serine protease inhibitor proteins
US6485968B1 (en) 1994-10-07 2002-11-26 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US6576238B1 (en) 1994-10-07 2003-06-10 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
EP1710252A3 (fr) * 1999-04-09 2006-12-27 Heska Corporation Molécules d'acides nucléiques et protéines issues de la tête, de la moelle épinière et du tube de Malpighi de puces et les utilisations correspondantes.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003156A1 (fr) * 1990-08-22 1992-03-05 Paravax, Inc. Vaccins antipuces derives de membranes
WO1993018788A1 (fr) * 1992-03-24 1993-09-30 The University Of Queensland Antigene de diagnostic et de desensibilisation concernant la dermatite allergique due aux mouches chez l'animal
US5418137A (en) * 1991-09-26 1995-05-23 Paravax, Inc. Flea membrane binding site proteins as screening tools

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003156A1 (fr) * 1990-08-22 1992-03-05 Paravax, Inc. Vaccins antipuces derives de membranes
US5418137A (en) * 1991-09-26 1995-05-23 Paravax, Inc. Flea membrane binding site proteins as screening tools
WO1993018788A1 (fr) * 1992-03-24 1993-09-30 The University Of Queensland Antigene de diagnostic et de desensibilisation concernant la dermatite allergique due aux mouches chez l'animal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, Volume 37, issued 1993, GREENE et al., "Isolation and in Vitro Translation of Messenger RNA Encoding Allergens of the Cat Flea, Ctenocephalides Felis", pages 15-23. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5927230A (en) * 1994-10-07 1999-07-27 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US6485968B1 (en) 1994-10-07 2002-11-26 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US6576238B1 (en) 1994-10-07 2003-06-10 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
WO1997037676A1 (fr) * 1996-04-10 1997-10-16 Heska Corporation Nouvelles proteines de salive d'ectoparasite et appareil pour les recueillir
US6368846B1 (en) 1996-04-10 2002-04-09 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
WO1998005772A1 (fr) * 1996-08-01 1998-02-12 Heska Corporation Facteur de liberation de l'histamine, d'ectoparasites, leurs genes et utilisations
US5952194A (en) * 1996-08-01 1999-09-14 Heska Corporation Flea nucleic acid sequences and uses thereof
US6063902A (en) * 1996-08-01 2000-05-16 Heska Corporation Ectoparasite histamine releasing factor, genes and uses thereof
US6372887B1 (en) * 1996-11-07 2002-04-16 Heska Corporation Flea serine protease inhibitor proteins
US6479253B1 (en) * 1996-11-07 2002-11-12 Heska Corporation Serine protease inhibitor nucleic acid molecules and uses thereof
WO2000061621A3 (fr) * 1999-04-09 2001-07-05 Heska Corp Molecules d'acides nucleiques et proteines issues de la tete, de la moelle epiniere, de l'intestin posterieur et du tube de malpighi de puces et utilisations correspondantes
EP1710252A3 (fr) * 1999-04-09 2006-12-27 Heska Corporation Molécules d'acides nucléiques et protéines issues de la tête, de la moelle épinière et du tube de Malpighi de puces et les utilisations correspondantes.

Also Published As

Publication number Publication date
AU3966895A (en) 1996-05-31

Similar Documents

Publication Publication Date Title
US5945294A (en) Method to detect IgE
McCall et al. Characterization and cloning of a major high molecular weight house dust mite allergen (Der f 15) for dogs
US7025962B1 (en) Mammalian cell surface antigens; related reagents
DE69634449T2 (de) Verfahren zum identifizieren von geschlechtsspezifischen und speziesspezifischen molekülen, mit verfahren identifizierte moleküle und verwendung der moleküle
JP2009159957A (ja) コナジラミエクジソン受容体核酸、ポリペプチド、およびそれらの使用
JP2009159958A (ja) ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
JPH08504179A (ja) Ｄｅｒｍａｔｏｐｈａｇｏｉｄｅｓ（室内塵ダニ）アレルゲンのクローニング及び配列決定
US20080038205A1 (en) Novel dermatophagoides proteins
US6060326A (en) Method to detect canine IgE and kit therefor
WO1996014089A1 (fr) Procedes et compositions pour diagnostiquer des allergies aux puces
US5552537A (en) IgE isoforms and methods of use
US7183386B2 (en) Feline immunoglobulin E proteins and compositions thereof
US5958880A (en) Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
JPH08506246A (ja) Ｇタンパク質結合型受容体ファミリーのヒトｔ細胞受容体
US20080286817A1 (en) Novel allergens and treatment
AU676828B2 (en) Antigens protective against (echinococcus granulosus) infection and vaccines containing such antigens
JPH08511432A (ja) Ｃｒｆ（副腎皮質刺激ホルモン放出因子）レセプターのクローニングおよび組換体の産生
DE60131962T2 (de) Verfahren und zusammensetzungen zum nachweis von taenia solium larven mittels eines klonierten antigens
US6297361B1 (en) Use of histidine decarboxylase immunoreactivity to detect human cancer
US7589187B2 (en) Dermatophagoides nucleic acid molecules
AU2001252799A1 (en) Sheep lice, Bovicola Ovis, Allergen Treatment
AU769954B2 (en) Method to detect IgE
WO2002022807A2 (fr) Nouvelles proteines et molecules d'acide nucleique de dermatophagoides et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase